Supernus Corp (SUPN): Price-to-Revenue Coefficient
Stable distribution channels eliminate supply disruptions for neuropreparations for Supernus Pharmaceuticals (SUPN). The estimated price-to-sales ratio visualizes the market valuation of assets, where the 2.70 level represents the current value. Market share protection is based on unique substance-release formulas. High scalability is ensured through subsequent global commercialization of products following successful clinical trials.
Analytical breakdowns for Supernus Corp (SUPN)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- company book value details:
- business debt structure and liquidity details:
- earnings and valuation multiples information:
SUPN - Net Profit|Future Profit Supernus Pharmaceuticals|SUPN - P/E Multiple|Projected Price to Earnings Ratio Supernus Pharmaceuticals|SUPN - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Supernus Pharmaceuticals|SUPN - Operating profit before deduction of amortization|Earnings per share for the last four quarters Supernus|SUPN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months supernus.com|SUPN - Earnings growth in current year|Expected earnings per share growth for next year Supernus Pharmaceuticals
- total revenue and sales volume data:
Fundamental company analysis:Supernus Pharmaceuticals, Inc., SUPN
For Supernus Pharmaceuticals (SUPN), whose revenues depend on long-term contracts with healthcare systems for the supply of CNS therapy drugs, the P/S levels on this chart reflect the market value of one dollar of revenue. The ratio of market capitalization to sales allows for an assessment of the premium paid for the business, where low values create a defensive buffer and high values increase the risk of a correction during a trend reversal.
Competitors of Supernus Pharmaceuticals
BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|CPRX (Catalyst Pharmaceuticals Inc) - P/S Multiple|DNLI: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio harmonybiosciences.com (HRMY)|Biohaven - Market Cap to Revenue Ratio|P/S Multiple AMLX (amylyx.com)|Trevi Pharma (TRVI) - Price to Sales|Praxis Corp - P/S Multiple|Anavex Corp (AVXL) - Market Cap to Revenue|CBLL: P/S Multiple|Prothena Biosciences - Market Capitalization-to-Revenue Ratio|ALEC (alector.com) - P/S Multiple|Market Cap to Revenue Ratio ANNX (Annexon Biosciences)|Price-to-Revenue Ratio Omeros Corporation (OMER)|Neurogene Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio AC Immune S.A. ACIU|Price-to-Revenue Coefficient Voyager Therapeutics (VYGR)|Neumora - P/S Multiple|Price-to-Sales Ratio SCLX|Tevogen Bio Inc. (TVGN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio ACOG|CGTX (cogrx.com) - P/S Multiple|Market Cap to Revenue inhibikase.com (IKT)|Price-to-Revenue Ratio Cassava Sciences Inc (SAVA)|Price-to-Revenue Coefficient Assertio|P/S Multiple COYA (Coya Therapeutics, Inc.)|Market Cap to Sales Volume VTGN (VistaGen Therapeutics Inc)|OVID: Market Cap to Revenue|ABOS: Price-to-Revenue Ratio|CervoMed (CRVO) - Price-to-Revenue Ratio|Price to Sales Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - P/S Multiple|Market Cap to Revenue Ratio PEPG (PepGen)|Market Cap to Revenue JUNS (Jupiter Neurosciences, Inc.)|P/S Multiple relmada.com (RLMD)|Price-to-Revenue Ratio Annovis Bio Corp ANVS|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (anewmeds.com) - Market Cap to Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Market Cap to Revenue|revivapharma.com - Market Capitalization-to-Revenue Ratio|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue
